



CENTER FOR MEDICARE

DATE: January 14, 2022

TO: All Prescription Drug Plans, Medicare Advantage-Prescription Drug Plans, Section 1876 Cost Plans, Medicare-Medicaid Plans, and PACE Organizations

FROM: Amy Larrick Chavez-Valdez
Director, Medicare Drug Benefit and C & D Data Group

SUBJECT: Part D Drug Management Program – Revised Standardized Beneficiary Notices, Model Documents, and Instructions

On December 29, 2021, CMS announced the availability of revised standardized beneficiary notices and instructions for Part D Drug Management Programs (DMPs), which were pending approval by the Office of Management and Budget (OMB). The purpose of this memorandum is to announce that those notices and instructions were approved by OMB on January 7, 2022.

Pursuant to 42 CFR § 423.153(f)(4)(c), Part D plan sponsors are required to communicate in writing with beneficiaries for whom they intend to limit access to coverage under a DMP. Sponsors must use approved, standardized beneficiary notices and may not develop their own. The revised notices contain updated language incorporating legislative and regulatory changes for DMPs, clarifications, and other improvements made after consideration of public comments.

While the revised notices are effective immediately, CMS recognizes it may take time for sponsors to update their systems with the revised language; therefore, sponsors will have until April 7, 2022 to fully implement use of the revised notices, and may continue to use the previous versions until that time. We strongly encourage sponsors to take any necessary steps to incorporate the revised notices into their DMP workflow as soon as possible.

We are also reposting updated model Prescriber Inquiry letters and Information Transfer Memos, with instructions, that plan sponsors may use to communicate with prescribers and other sponsors, as appropriate, as part of their DMPs. Sponsors may use all or part of the language in the models, modify the language, or create their own language.

The standardized beneficiary notices and instructions, as well as the model documents, are available [here](#) on the [CMS Part D Overutilization web page](#) in the Downloads section. For additional information about the use of these documents, refer to the accompanying instructions and the [CY 2022 Part D DMP Guidance](#).

Questions about DMPs and these notices may be submitted to PartD_OM@cms.hhs.gov.